Etanercept: Efficacy and safety for approved indications

Expert Opinion on Drug Safety

Volumn 11, Issue 1, 2012, Pages 121-139

  Kerensky, Todd A ^a   Gottlieb, Alice B ^a   Yaniv, Shimrat ^b   Au, Shiu Chung ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Ankylosing spondylitis; Beh et's disease; Etanercept; Juvenile idiopathic arthritis; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Tumor necrosis factor alpha inhibitors

Indexed keywords

ADALIMUMAB; ANTIVIRUS AGENT; C REACTIVE PROTEIN; CORTICOSTEROID; CYCLOSPORIN; DIGOXIN; ETANERCEPT; GOLD; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; PLACEBO; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; WARFARIN;

ALCOHOL LIVER DISEASE; ANKYLOSING SPONDYLITIS; APLASTIC ANEMIA; ARTHRALGIA; ARTICLE; ASPERGILLOSIS; BEHCET DISEASE; CANDIDIASIS; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; CRYPTOCOCCOSIS; DEMYELINATING DISEASE; DRUG MEGADOSE; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; GASTROINTESTINAL PAIN; HEART FAILURE; HEPATITIS B; HEPATITIS C; HERPES SIMPLEX; HERPES ZOSTER; HISTOPLASMOSIS; HUMAN; INFECTION RISK; INJECTION SITE REACTION; JOINT SWELLING; JUVENILE RHEUMATOID ARTHRITIS; LACTATION; LATENT TUBERCULOSIS; LEUKEMIA; LEUKOPENIA; LOW DRUG DOSE; LYMPHOMA; MELANOMA; MORNING STIFFNESS; MULTIPLE SCLEROSIS; MYELITIS; MYELODYSPLASTIC SYNDROME; OPPORTUNISTIC INFECTION; OPTIC NEURITIS; PANCYTOPENIA; PHOTOTHERAPY; PLANTAR FASCIITIS; POSTMARKETING SURVEILLANCE; PREGNANCY; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN CANCER; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T CELL LEUKEMIA; T CELL LYMPHOMA; TERATOGENICITY; THROMBOCYTOPENIA; UVEITIS; WEGENER GRANULOMATOSIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84555190222     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2012.633509     Document Type: Article

References (172)

1. Culy CR, Keating GM. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Drugs 2002;62:2493-537 (Pubitemid 35448141)
2. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008;117:244-79
3. Tan JK, Aphale A, Malaviya R, et al. Mechanisms of action of etanercept in psoriasis. J Investig Dermatol Symp Proc 2007;12:38-45 (Pubitemid 46763034)
4. Korth-Bradley JM, Rubin AS, Hanna RK, et al. The pharmacokinetics of etanercept in healthy volunteers. Ann Pharmacother 2000;34:161-4 (Pubitemid 30082972)
5. Zhou H. Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. J Clin Pharmacol 2005;45:490-7 (Pubitemid 40562938)
6. Nestorov I, Zitnik R, DeVries T, et al. Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis. Br J Clin Pharmacol 2006;62:435-45 (Pubitemid 44401526)
7. Zhou H, Buckwalter M, Boni J, et al. Population-based pharmacokinetics of the soluble TNFr etanercept: a clinical study in 43 patients with ankylosing spondylitis compared with post hoc data from patients with rheumatoid arthritis. Int J Clin Pharmacol Ther 2004;42:267-76 (Pubitemid 38679015)
8. Lee H, Kimko HC, Rogge M, et al. Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin Pharmacol Ther 2003;73:348-65 (Pubitemid 36403595)
9. Yim DS, Zhou H, Buckwalter M, et al. Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis. J Clin Pharmacol 2005;45:246-56 (Pubitemid 40490422)
10. Clark L, Lebwohl M. The effect of weight on the efficacy of biologic therapy in patients with psoriasis. J Am Acad Dermatol 2008;58:443-6
11. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81 (Pubitemid 38296553)
12. Zhou H, Mayer PR, Wajdula J, et al. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. J Clin Pharmacol 2004;44:1235-43 (Pubitemid 39391482)
13. Zhou H, Patat A, Parks V, et al. Absence of a pharmacokinetic interaction between etanercept and warfarin. J Clin Pharmacol 2004;44:543-50 (Pubitemid 38509724)
14. Zhou H, Parks V, Patat A, et al. Absence of a clinically relevant interaction between etanercept and digoxin. J Clin Pharmacol 2004;44:1244-51 (Pubitemid 39391483)
15. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130:478-86 (Pubitemid 29135800)
16. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9 (Pubitemid 29063266)
17. O'Dell JR, Petersen K, Leff R, et al. Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis. J Rheumatol 2006;33:213-18 (Pubitemid 43209293)
18. Combe B, Codreanu C, Fiocco U, et al. Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. Ann Rheum Dis 2006;65:1357-62 (Pubitemid 44620447)
19. Combe B, Codreanu C, Fiocco U, et al. Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study. Ann Rheum Dis 2009;68:1146-52
20. Keystone EC, Schiff MH, Kremer JM, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50:353-63 (Pubitemid 38198818)
21. Johnsen AK, Schiff MH, Mease PJ, et al. Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study. J Rheumatol 2006;33:659-64
22. Sharp JT, Lidsky MD, Collins LC, et al. Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum 1971;14:706-20
23. Sharp JT, Bluhm GB, Brook A, et al. Reproducibility of multiple-observer scoring of radiologic abnormalities in the hands and wrists of patients with rheumatoid arthritis. Arthritis Rheum 1985;28:16-24 (Pubitemid 15193017)
24. Fries JF, Bloch DA, Sharp JT, et al. Assessment of radiologic progression in rheumatoid arthritis. A randomized, controlled trial. Arthritis Rheum 1986;29:1-9 (Pubitemid 17015400)
25. Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45 (Pubitemid 10164318)
26. Lovell DJ, Giannini EH, Reiff A, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763-9 (Pubitemid 30151920)
27. Lovell DJ, Reiff A, Ilowite NT, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008;58:1496-504 (Pubitemid 351705939)
28. Lovell DJ, Reiff A, Jones OY, et al. Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2006;54:1987-94 (Pubitemid 43877949)
29. Nielsen S, Ruperto N, Gerloni V, et al. Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis. Clin Exp Rheumatol 2008;26:688-92
30. Poznanski AK, Hernandez RJ, Guire KE, et al. Carpal length in children-a useful measurement in the diagnosis of rheumatoid arthritis and some concenital malformation syndromes. Radiology 1978;129:661-8 (Pubitemid 9059971)
31. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90 (Pubitemid 30487495)
32. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35
33. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264-72 (Pubitemid 38924405)
34. Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006;33:712-21
35. Kristensen LE, Gulfe A, Saxne T, et al. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Ann Rheum Dis 2008;67:364-9 (Pubitemid 351281272)
36. Daly M, Alikhan A, Armstrong AW. Combination systemic therapies in psoriatic arthritis. J Dermatolog Treat 2011 Oct; 22(1):276-84
37. Spadaro A, Ceccarelli F, Scrivo R, et al. Life-table analysis of etanercept with or without methotrexate in patients with psoriatic arthritis. Ann Rheum Dis 2008;67:1650-1
38. Heiberg MS, Koldingsnes W, Mikkelsen K, et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum 2008;59:234-40 (Pubitemid 351272960)
39. Duclos M, Gossec L, Ruyssen-Witrand A, et al. Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients. J Rheumatol 2006;33:2433-8
40. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002;346:1349-56 (Pubitemid 34754607)
41. Anderson JJ, Baron G, van der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86 (Pubitemid 32758236)
42. Davis JC Jr, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-6 (Pubitemid 37409337)
43. Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003;48:1667-75 (Pubitemid 36682375)
44. Calin A, Dijkmans BA, Emery P, et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 2004;63:1594-600 (Pubitemid 39573687)
45. Davis JC Jr, van der Heijde DM, Braun J, et al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 2008;67:346-52 (Pubitemid 351281269)
46. Dijkmans B, Emery P, Hakala M, et al. Etanercept in the longterm treatment of patients with ankylosing spondylitis. J Rheumatol 2009;36:1256-64
47. Brandt J, Listing J, Haibel H, et al. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology (Oxford) 2005;44:342-8 (Pubitemid 40361291)
48. Braun J, McHugh N, Singh A, et al. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Rheumatology (Oxford) 2007;46:999-1004 (Pubitemid 47062511)
49. Baraliakos X, Hermann KG, Landewe R, et al. Assessment of acute spinal inflammation in patients with ankylosing spondylitis by magnetic resonance imaging: a comparison between contrast enhanced T1 and short tau inversion recovery (STIR) sequences. Ann Rheum Dis 2005;64:1141-4 (Pubitemid 41113347)
50. Braun J, Baraliakos X, Golder W, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 2003;48:1126-36 (Pubitemid 36418256)
51. Baraliakos X, Brandt J, Listing J, et al. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum 2005;53:856-63 (Pubitemid 41811126)
52. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014-22 (Pubitemid 37448924)
53. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-16 (Pubitemid 24194579)
54. Feldman SR, Kimball AB, Krueger GG, et al. Etanercept improves the health-related quality of life of patients with psoriasis: results of a phase III randomized clinical trial. J Am Acad Dermatol 2005;53:887-9 (Pubitemid 41501389)
55. Gottlieb AB, Matheson RT, Lowe N, et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003;139:1627-32.discussion 32
56. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006;367:29-35 (Pubitemid 43038667)
57. Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007;143:719-26 (Pubitemid 46955730)
58. Gambichler T, Tigges C, Scola N, et al. Etanercept plus narrowband ultraviolet B phototherapy of psoriasis is more effective than etanercept monotherapy at 6 weeks. Br J Dermatol 2011;164:1383-6
59. Wolf P, Hofer A, Legat FJ, et al. Treatment with 311-nm ultraviolet B accelerates and improves the clearance of psoriatic lesions in patients treated with etanercept. Br J Dermatol 2009;160:186-9
60. De Simone C, D'Agostino M, Capizzi R, et al. Combined treatment with etanercept 50 mg once weekly and narrow-band ultraviolet B phototherapy in chronic plaque psoriasis. Eur J Dermatol 2011 July-Aug; 21(4):588-72
61. Kircik L, Bagel J, Korman N, et al. Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes. J Drugs Dermatol 2008;7:245-53
62. Di Lernia V, Albertini G. Is antitumour necrosis factor therapy combined with ultraviolet B phototherapy safe? Br J Dermatol 2010;162:1147-8
63. Arida A, Fragiadaki K, Giavri E, et al. Anti-TNF agents for Behcet's disease: analysis of published data on 369 patients. Semin Arthritis Rheum 2011;41(1):61-70
64. Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behcet's disease: a double blind, placebo controlled study. J Rheumatol 2005;32:98-105 (Pubitemid 40092599)
65. Saurenmann RK, Levin AV, Rose JB, et al. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis. Rheumatology (Oxford) 2006;45:982-9 (Pubitemid 44283053)
66. Cantarini L, Tinazzi I, Caramaschi P, et al. Safety and efficacy of etanercept in children with juvenile-onset Behcets disease. Int J Immunopathol Pharmacol 2009;22:551-5
67. Alty JE, Monaghan TM, Bamford JM. A patient with neuro-Behcet's disease is successfully treated with etanercept: further evidence for the value of TNFalpha blockade. Clin Neurol Neurosurg 2007;109:279-81
68. Aeberli D, Oertle S, Mauron H, et al. Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. Swiss Med Wkly 2002;132:414-22 (Pubitemid 35303463)
69. Curigliano V, Giovinale M, Fonnesu C, et al. Efficacy of etanercept in the treatment of a patient with Behcet's disease. Clin Rheumatol 2008;27:933-6
70. Zhang MF, Zhao C, Wen X, et al. The short-term efficacy and safety treatment study of recurrent uveitis in Behcet disease with etanercept. Zhonghua Yan Ke Za Zhi 2010;46:145-50
71. Borhani Haghighi A. Treatment of neuro-Behcet's disease: an update. Expert Rev Neurother 2009;9:565-74
72. Singh JA, Christensen R, Wells GA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 2009;CD007848
73. Gottlieb AB, Gordon K, Giannini EH, et al. Clinical trial safety and mortality analyses in patients receiving etanercept across approved indications. J Drugs Dermatol 2011;10:289-300
74. Wood KL, Hage CA, Knox KS, et al. Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy. Am J Respir Crit Care Med 2003;167:1279-82 (Pubitemid 36555102)
75. Giles JT, Bathon JM. Serious infections associated with anticytokine therapies in the rheumatic diseases. J Intensive Care Med 2004;19:320-34 (Pubitemid 44544695)
76. Zaman R, Abbas M. Case report of fatal disseminated histoplasmosis in a patient with rheumatoid arthritis following therapy with etanercept and methotrexate. In 40th Annual Meeting of the Infectious Diseases Society of America 2002; Chicago IL
77. Bourre-Tessier J, Fortin C, Belisle A, et al. Disseminated Histoplasma capsulatum infection presenting with panniculitis and focal myositis in rheumatoid arthritis treated with etanercept. Scand J Rheumatol 2009;38:311-16
78. Bakleh M, Tleyjeh I, Matteson EL, et al. Infectious complications of tumor necrosis factor-alpha antagonists. Int J Dermatol 2005;44:443-8 (Pubitemid 40867546)
79. Smitten AL, Choi HK, Hochberg MC, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 2007;57:1431-8 (Pubitemid 350308841)
80. Wolfe F, Michaud K, Chakravarty EF. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology (Oxford) 2006;45:1370-5 (Pubitemid 44605471)
81. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009;301:737-44
82. Garcia-Doval I, Perez-Zafrilla B, Descalzo MA, et al. Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Ann Rheum Dis 2010;69:1751-5
83. Salmon-Ceron D, Tubach F, Lortholary O, et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 2011;70:616-23
84. Bassetti S, Wasmer S, Hasler P, et al. Staphylococcus aureus in patients with rheumatoid arthritis under conventional and anti-tumor necrosis factor-alpha treatment. J Rheumatol 2005;32:2125-9 (Pubitemid 41587855)
85. Jacobson JJ, Patel B, Asher G, et al. Oral staphylococcus in older subjects with rheumatoid arthritis. J Am Geriatr Soc 1997;45:590-3 (Pubitemid 27213128)
86. Jackson MS, Bagg J, Gupta MN, et al. Oral carriage of staphylococci in patients with rheumatoid arthritis. Rheumatology (Oxford) 1999;38:572-5 (Pubitemid 29504846)
87. Bassetti S, Dunagan DP, D'Agostino RB Jr, et al. Nasal carriage of Staphylococcus aureus among patients receiving allergen-injection immunotherapy: associated factors and quantitative nasal cultures. Infect Control Hosp Epidemiol 2001;22:741-5 (Pubitemid 34157714)
88. Kluytmans J, van Belkum A, Verbrugh H. Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms, and associated risks. Clin Microbiol Rev 1997;10:505-20 (Pubitemid 27359263)
89. Bassetti S, Wolfisberg L, Jaussi B, et al. Carriage of Staphylococcus aureus among injection drug users: lower prevalence in an injection heroin maintenance program than in an oral methadone program. Infect Control Hosp Epidemiol 2004;25:133-7 (Pubitemid 38252343)
90. Sweet DD, Isac G, Morrison B, et al. Purulent pericarditis in a patient with rheumatoid arthritis treated with etanercept and methotrexate. CJEM 2007;9:40-2 (Pubitemid 46277259)
91. Braun J, Baraliakos X, Brandt J, et al. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) 2005;44:670-6 (Pubitemid 41487242)
92. Mohan AK, Cote TR, Block JA, et al. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 2004;39:295-9 (Pubitemid 39050474)
93. Carmona L, Hernandez-Garcia C, Vadillo C, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 2003;30:1436-9 (Pubitemid 36835436)
94. Aggarwal R, Manadan AM, Poliyedath A, et al. Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections. J Rheumatol 2009;36:914-17
95. Frankel AJ, Van Voorhees AS, Hsu S, et al. Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2009;61:1044-55
96. Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005;42:315-22 (Pubitemid 40254244)
97. Gandhi RK, Pickup T, Sheth PB. Is etanercept safe for treating plaque psoriasis in a patient with chronic hepatitis C virus infection? Arch Dermatol 2010;146:1151-2
98. Zingarelli S, Frassi M, Bazzani C, et al. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature. J Rheumatol 2009;36:1188-94
99. Vassilopoulos D, Apostolopoulou A, Hadziyannis E, et al. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis 69:1352-5
100. Elkayam O, Caspi D, Reitblatt T, et al. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum 2004;33:283-8 (Pubitemid 38280827)
101. Kapetanovic MC, Saxne T, Sjoholm A, et al. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006;45:106-11 (Pubitemid 43033885)
102. Mease PJ, Ritchlin CT, Martin RW, et al. Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol 2004;31:1356-61 (Pubitemid 38879202)
103. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 2005;165:2337-44 (Pubitemid 41640845)
104. Askling J, Fored CM, Baecklund E, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005;64:1414-20 (Pubitemid 41623850)
105. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum 2006;54:692-701
106. Grimpen F, Yeung D, Joseph J. Hepatosplenic T Cell lympoma, immunosuppressive agents and biologicals: what are the risks? J Gastroenterol Hepatol 2009;24:A311
107. Beyer M, Steinhoff M, Anagnostopoulos I, et al. Hepatosplenic T-cell lymphomas and therapy with TNF-alpha-blocking biologics: a risk for psoriasis patients? J Dtsch Dermatol Ges 2009;7:191-4
108. Praiser DM, Leonardi C, Gordon K, et al. Integrated safety analysis: Short-and long-term safety profiles of etanercept in patients with psoriasis. J Am Acad Dermatol 2011Oct 18 Epub ahead of print
109. Gray DT, Suman VJ, Su WP, et al. Trends in the population-based incidence of squamous cell carcinoma of the skin first diagnosed between 1984 and 1992. Arch Dermatol 1997;133:735-40 (Pubitemid 27263707)
110. Harris RB, Griffith K, Moon TE. Trends in the incidence of nonmelanoma skin cancers in southeastern Arizona, 1985-1996. J Am Acad Dermatol 2001;45:528-36 (Pubitemid 32917246)
111. Gelfand JM, Shin DB, Neimann AL, et al. The risk of lymphoma in patients with psoriasis. J Invest Dermatol 2006;126:2194-201 (Pubitemid 44413165)
112. Gelfand JM, Berlin J, Van Voorhees A, et al. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol 2003;139:1425-9 (Pubitemid 37433132)
113. Margolis D, Bilker W, Hennessy S, et al. The risk of malignancy associated with psoriasis. Arch Dermatol 2001;137:778-83 (Pubitemid 32577862)
114. Hodgson NC. Merkel cell carcinoma: changing incidence trends. J Surg Oncol 2005;89:1-4 (Pubitemid 40075960)
115. Reichgelt BA, Visser O. Epidemiology and survival of Merkel cell carcinoma in the Netherlands. A population-based study of 808 cases in 1993-2007. Eur J Cancer 2011;47:579-85
116. McCroskery P, Wallace CA, Lovell DJ, et al. Summary of worldwide pediatric malignancies reported after exposure to etanercept. Pediatr Rheumatol Online J 2010;8:18
117. Hayward K, Wallace CA. Recent developments in anti-rheumatic drugs in pediatrics: treatment of juvenile idiopathic arthritis. Arthritis Res Ther 2009;11:216
118. Breda L, Del Torto M, De Sanctis S, et al. Biologics in children's autoimmune disorders: efficacy and safety. Eur J Pediatr 2011;170:157-67
119. Diak P, Siegel J, La Grenade L, et al. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum 2010;62:2517-24
120. Cron RQ, Beukelman T. Guilt by association-what is the true risk of malignancy in children treated with etanercept for JIA? Pediatr Rheumatol Online J 2010;8:23
121. Mercieca C, Vella N, Borg AA. Demyelination during anti-TNFalpha therapy for ankylosing spondylitis. Mod Rheumatol 2011 July; 12 Epub ahead of print
122. Alshekhlee A, Basiri K, Miles JD, et al. Chronic inflammatory demyelinating polyneuropathy associated with tumor necrosis factor-alpha antagonists. Muscle Nerve 41:723-7
123. Pfueller CF, Seipelt E, Zipp F, et al. Multiple sclerosis following etanercept treatment for ankylosing spondylitis. Scand J Rheumatol 2008;37:397-9
124. Do HH, Mohamed A, Klistorner A, et al. Ophthalmic manifestations of demyelination secondary to etanercept. Clin Experiment Ophthalmol 2008;36:392-4 (Pubitemid 352015187)
125. Gomez-Gallego M, Meca-Lallana J, Fernandez-Barreiro A. Multiple sclerosis onset during etanercept treatment. Eur Neurol 2008;59:91-3 (Pubitemid 350277270)
126. Fromont A, De Seze J, Fleury MC, et al. Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine 2009;45:55-7
127. Lozeron P, Denier C, Lacroix C, et al. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol 2009;66:490-7
128. Cay HF, Gungor HA, Sezer I, et al. Adverse effect of TNF-alpha blocker? Demyelination in an ankylosing spondylitis patient: a case report. J Clin Pharm Ther 2006;31:645-8 (Pubitemid 44813778)
129. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862-9 (Pubitemid 34016206)
130. Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 2001;57:1885-8 (Pubitemid 33096700)
131. Richez C, Blanco P, Lagueny A, et al. Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers. Neurology 2005;64:1468-70 (Pubitemid 40570527)
132. van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996;47:1531-4 (Pubitemid 26422549)
133. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999;53:457-65
134. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58:826-50 (Pubitemid 351509656)
135. Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236-41 (Pubitemid 20225044)
136. Deswal A, Bozkurt B, Seta Y, et al. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation 1999;99:3224-6 (Pubitemid 29293430)
137. Bozkurt B, Torre-Amione G, Warren MS, et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation 2001;103:1044-7 (Pubitemid 32200174)
138. Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004;109:1594-602 (Pubitemid 38451714)
139. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004;116:305-11 (Pubitemid 38230289)
140. Yang DH, Chang DM, Lai JH, et al. Etanercept as a rescue agent in patient with adult onset Still's disease complicated with congestive heart failure. Rheumatol Int 2008;29:95-8
141. Kwon HJ, Cote TR, Cuffe MS, et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003;138:807-11
142. Kuruvilla J, Leitch HA, Vickars LM, et al. Aplastic anemia following administration of a tumor necrosis factor-alpha inhibitor. Eur J Haematol 2003;71:396-8 (Pubitemid 37330515)
143. Quartier P, Taupin P, Bourdeaut F, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003;48:1093-101 (Pubitemid 36418252)
144. Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-alpha antagonists. Drug Saf 2004;27:307-24 (Pubitemid 38530461)
145. Feltelius N, Fored CM, Blomqvist P, et al. Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. Ann Rheum Dis 2005;64:246-52 (Pubitemid 40193621)
146. Williams VL, Cohen PR. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists. Int J Dermatol 2011;50:619-25
147. Ramos-Casals M, Brito-Zeron P, Munoz S, et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007;86:242-51 (Pubitemid 47067483)
148. Porfyridis I, Kalomenidis I, Psallidas I, et al. Etanercept-induced pleuropericardial lupus-like syndrome. Eur Respir J 2009;33:939-41
149. Kang MJ, Lee YH, Lee J. Etanercept-induced systemic lupus erythematosus in a patient with rheumatoid arthritis. J Korean Med Sci 2006;21:946-9 (Pubitemid 44611236)
150. Carlson E, Rothfield N. Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis. Arthritis Rheum 2003;48:1165-6.author reply 6
151. Jonsdottir T, Forslid J, van Vollenhoven A, et al. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann Rheum Dis 2004;63:1075-8 (Pubitemid 39120357)
152. Amgen, Etanercept Physician Package Insert. 2003
153. Shakoor N, Michalska M, Harris CA, et al. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002;359:579-80 (Pubitemid 34178442)
154. Cairns AP, Duncan MK, Hinder AE, et al. New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis. Ann Rheum Dis 2002;61:1031-2 (Pubitemid 35221697)
155. Mohan AK, Edwards ET, Cote TR, et al. Drug-induced systemic lupus erythematosus and TNF-alpha blockers. Lancet 2002;360:646
156. De Bandt M, Sibilia J, Le Loet X, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005;7:R545-51
157. Zeltser R, Valle L, Tanck C, et al. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor alpha receptor: Fc fusion protein. Arch Dermatol 2001;137:893-9 (Pubitemid 32641648)
158. Gonzalez-Lopez MA, Martinez-Taboada VM, Gonzalez-Vela MC, et al. Recall injection-site reactions associated with etanercept therapy: report of two new cases with immunohistochemical analysis. Clin Exp Dermatol 2007;32:672-4 (Pubitemid 47609740)
159. de Gannes GC, Ghoreishi M, Pope J, et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol 2007;143:223-31 (Pubitemid 46294587)
160. Peek R, Scott-Jupp R, Strike H, et al. Psoriasis after treatment of juvenile idiopathic arthritis with etanercept. Ann Rheum Dis 2006;65:1259 (Pubitemid 44277417)
161. Chen LA, Su LH, Chang YJ, et al. New-onset psoriasis associated with etanercept therapy. J Dermatol 37:378-80
162. Harrison MJ, Dixon WG, Watson KD, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2009;68:209-15
163. Fleischmann R, Baumgartner SW, Weisman MH, et al. Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis 2006;65:379-84 (Pubitemid 43268229)
164. Militello G, Xia A, Stevens SR, et al. Etanercept for the treatment of psoriasis in the elderly. J Am Acad Dermatol 2006;55:517-19 (Pubitemid 44189579)
165. Background Information For The Dermatologic and Ophthalmologic Drugs Advisory Committee (DODAC) Meeting 2008; Amgen Briefing Document for the United States Food and Drug Administration Dermatologic and Ophthalmic Drug Advisory Committee Meeting; 18 June 2008. Available from: http://www.fda.gov/ohrms/ dockets/ac/08/briefing/2008-4361b2-02-AMGEN.pdf Cited 11 February 2011
166. Reed SD, Vollan TA, Svec MA. Pregnancy outcomes in women with rheumatoid arthritis in Washington State. Matern Child Health J 2006;10:361-6
167. Murashima A, Watanabe N, Ozawa N, et al. Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant's serum. Ann Rheum Dis 2009;68:1793-4
168. Ostensen M, Eigenmann GO. Etanercept in breast milk. J Rheumatol 2004;31:1017-18
169. Boetticher NC, Peine CJ, Kwo P, et al. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 2008;135:1953-60
170. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for N Engl J Med 2005;352:351-61
171. Genovese MC, Cohen S, Moreland L, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum 2004;50:1412-19 (Pubitemid 38608062)
172. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93 (Pubitemid 32162981)